uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials
GSK, Ave Fleming 20, B-1300 Wavre, Belgium.
GSK, Ave Fleming 20, B-1300 Wavre, Belgium.
GSK, Ave Fleming 20, B-1300 Wavre, Belgium.
GSK, Rixensart, Belgium.
Show others and affiliations
2019 (English)In: Vaccine, ISSN 0264-410X, E-ISSN 1873-2518, Vol. 37, no 18, p. 2482-2493Article in journal (Refereed) Published
Abstract [en]

Background: The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was >= 90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.

Methods: Adults aged >= 50 (ZOE-50) and >= 70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30 days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12 months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.

Results: Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.

Conclusions: No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 

Place, publisher, year, edition, pages
ELSEVIER SCI LTD , 2019. Vol. 37, no 18, p. 2482-2493
Keywords [en]
Varicella-zoster virus, Vaccine, Safety, Reactogenicity
National Category
General Practice
Identifiers
URN: urn:nbn:se:uu:diva-387212DOI: 10.1016/j.vaccine.2019.03.043ISI: 000466622500009PubMedID: 30935742OAI: oai:DiVA.org:uu-387212DiVA, id: diva2:1330190
Available from: 2019-06-25 Created: 2019-06-25 Last updated: 2019-06-25Bibliographically approved

Open Access in DiVA

fulltext(485 kB)97 downloads
File information
File name FULLTEXT01.pdfFile size 485 kBChecksum SHA-512
d4356423b58c32d9f7ac14cb65b3ee73bc947d9e091c53a3f949917533cbae541cc8c1b9b42c814cfde6a58446c9ab3217701496ace2a6b18efb11a8fea20149
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records BETA

Pauksen, KarlisRombo, Lars

Search in DiVA

By author/editor
Yeo, WilfredPauksen, KarlisRombo, Lars
By organisation
Infectious DiseasesCentrum för klinisk forskning i Sörmland (CKFD)
In the same journal
Vaccine
General Practice

Search outside of DiVA

GoogleGoogle Scholar
Total: 97 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 103 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf